Cardiac muscle regeneration using mesenchymal stem cells
AssigneeOsiris Therapeutics, Inc.
InventorsMark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
Claims17
A process for producing cardiac muscle cells in the heart of an individual in need thereof, comprising:
- administering to said individual autologoue or allogenic mesenchymal stem cells in an amount effective to produce cardiac muscle cells in the heart of said individual, said administered mesenchymal stem cells differentiating into cardiac muscle cells thereby producing cardiac muscle cells in the heart of said individual.
A process for reducing scar formation in infarcted heart tissue, comprising:
- administering to an individual having infarcted heart tissue autologous or allogenic mesenchymal stem cells in an amount effective to produce cardiac muscle cells in the heart of said individual, said administered mesenchymal stem cells differentiating into cardiac muscle cells, and wherein said cardiac muscle cells produce cardiac muscle, thereby reducing scar formation in said infarcted heart tissue.
Dependencies are inferred from the claim text.